EyePoint Pharmaceuticals Grants Stock Options to New Employees

EyePoint Pharmaceuticals, a leading company dedicated to developing and commercializing therapeutics for serious eye disorders, has recently announced the granting of non-statutory stock options to new employees. These inducement awards were given outside the Company’s 2023 Long-Term Incentive Plan, in accordance with NASDAQ Listing Rule 5635(c)(4).

The stock options were granted to two new employees, allowing them to purchase up to a total of 4,000 shares of EyePoint Pharmaceuticals common stock. The grants were approved by the Compensation Committee and were considered a material inducement for each employee entering into employment with the company.

The exercise price for the stock options is set at $10.48 per share, which reflects the closing price of EyePoint Pharmaceuticals’ common stock on September 15, 2023. These options have a ten-year term and will vest over a period of four years. The vesting schedule includes 25% of the original number of shares vesting on the first anniversary of the employee’s grant date, with the remaining shares vesting in equal monthly installments over the following three years. Continued service with EyePoint Pharmaceuticals is required for the options to fully vest.

EyePoint Pharmaceuticals, headquartered in Watertown, Massachusetts, is focused on leveraging its proprietary erodible Durasert E™ technology for sustained intraocular drug delivery. The company’s pipeline includes EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. With a proven track record of safe administration to thousands of patients, EyePoint Pharmaceuticals is dedicated to improving the lives of individuals with serious eye disorders.

For more information about EyePoint Pharmaceuticals and its innovative therapies, please visit www.eyepointpharma.com.

Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com